Elite in Autoimmune Hemolytic Anemia

Tor A. Tvedt

Oslo, NO 
Elite in Autoimmune Hemolytic Anemia
Oslo, NO 
OverviewLocationsClinical Research

Overview

Tor Tvedt practices in Oslo, Norway. Mr. Tvedt is rated as an Elite expert by MediFind in the treatment of Autoimmune Hemolytic Anemia. His top areas of expertise are Autoimmune Hemolytic Anemia, Hemolysis, Hemolytic Anemia, Anemia, and Bone Marrow Transplant.

His clinical research consists of co-authoring 66 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 10 articles and participated in 2 clinical trials in the study of Autoimmune Hemolytic Anemia.

Gender
Male

Locations

Oslo, Norway
Other Locations
Bergen, Norway

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
Enrollment Status: Completed
Publish Date: May 25, 2023
Intervention Type: Drug
Study Drug: Fostamatinib
Study Phase: Phase 3
The CAD5 Study::Therapy for Chronic Cold Agglutinin Disease: A Prospective, Non-randomized International Multicenter Trial on the Safety and Efficacy of Bendamustine and Rituximab Combination Therapy
The CAD5 Study::Therapy for Chronic Cold Agglutinin Disease: A Prospective, Non-randomized International Multicenter Trial on the Safety and Efficacy of Bendamustine and Rituximab Combination Therapy
Enrollment Status: Completed
Publish Date: January 09, 2017
Intervention Type: Drug
Study Phase: Phase 2
View 1 Less Clinical Trial

65 Total Publications

Safety and Efficacy of Daratumumab in Immune Thrombocytopenia.
Safety and Efficacy of Daratumumab in Immune Thrombocytopenia.
Journal: Blood advances
Published: May 28, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Tvedt's expertise for a condition
ConditionClose
View All 23 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile